Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 307
- Registration Number
- NCT02604823
Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 64
- Registration Number
- NCT02601976
A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 255
- Registration Number
- NCT02598063
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 294
- Registration Number
- NCT02589652
- Locations
- 🇨🇳
The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China
🇨🇳Fuzhou Municipal Infectious Disease Hospital, Fuzhou, Fujian, China
🇨🇳The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT02576964
A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT02570191
A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT02556307
Directly Observed Therapy for HCV in Chennai, India
- Conditions
- Interventions
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 50
- Registration Number
- NCT02541409
- Locations
- 🇮🇳
YR Gaitonde Centre for AIDS Research and Education, Chennai, Tamil Nadu, India
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 463
- Registration Number
- NCT02515279
- Locations
- 🇦🇹
A.Ö. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl., Ried-innkreis, Austria
Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients
- Conditions
- Interventions
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 366
- Registration Number
- NCT02474316
- Locations
- 🇨🇳
The Third People's Hospital of Guilin, Guilin, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, China
🇨🇳Ruijin Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.